Recruiting

Surgical Innovation

Sponsor:

UCLA

Code:

NCT06783751

Conditions

Obesity

Bariatric Surgery

Sleeve Gastrectomy

Gastroesophageal Reflux Disease

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Modified Vertical Sleeve Gastrectomy (mVSG)

Conventional Vertical Sleeve Gastrectomy (cVSG)

Study Details

Brief summary:

This is a two-site randomized clinical trial aiming to test whether a modified investigational bariatric surgical procedure can improve gastroesophageal reflux disease (GERD) after sleeve gastrectomy.

Conditions

Obesity

Bariatric Surgery

Sleeve Gastrectomy

Gastroesophageal Reflux Disease

Study ID

NCT06783751

Start date

Mar 21, 2025

Status verified date

Jul, 2026

Completion date

Jul 1, 2028

Anticipated

Primary completion date

Apr 30, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Male and female subjects aged 18-65 years
2. Body mass index (BMI) 35-55 kg/m2
3. Must meet the BMI criteria before and after 6 months of nonsurgical weight management
4. Presence of GERD defined for this trial as acid exposure time (AET) of 4.9% or above as assessed with the Bravo pH test.
5. Have health insurance which pays for the costs of bariatric surgery and standard medical care before and after surgery
6. Women of childbearing potential must be using appropriate contraception to avoid pregnancy throughout the study, and must have a negative pregnancy test at study entry and prior to surgery
7. Must be able to provide written informed consent

Exclusion Criteria:

1. Hiatal hernia >2cm (defined as maximum axial height from end of the esophagus to diaphragm by any study including upper endoscopy esophagram and or at the time of surgery)
2. Evidence of clinically significant major esophageal motility disorder as determined by the site primary investigator
3. Severe gastroparesis
4. Previous bariatric or anti-reflux procedure
5. Barrett's esophagus
6. Subjects requiring mesh treatment at time of procedure
7. Severe heart (e.g., severe heart failure, unstable coronary artery disease), or end-stage lung disease as determined by the site primary investigator
8. Subjects with pacemakers, implantable defibrillators, neurostimulators
9. Portal hypertension or cirrhosis
10. Chronic pancreatitis
11. Active cancer treatment
12. Inability to tolerate general anesthesia
13. Uncontrollable coagulopathy
14. Significant and uncontrolled inflammatory bowel disease
15. Severe and/or uncontrolled psychiatric disorder (including psychosis, bipolar disorder) as determined during standard pre-surgery psychiatric screening at the site.
16. Suicidal ideation or unstable/untreated major depressive disorder within the past year
17. Alcohol or substance use disorder within the past year.
18. Pregnant or breastfeeding or planning pregnancy in the coming 24 months
19. Diminished intellectual capacity to consent or follow pre- and post-surgery instructions
20. History of, or any current health condition that, in the opinion of the PI, would make the subject ineligible for sleeve gastrectomy, or put the subject at risk by participation in the study.

Study Design

Enrollment

44 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Modified Vertical Sleeve Gastrectomy (mVSG)

modified investigational vertical sleeve gastrectomy (mVSG)

active comparator: Conventional Vertical Sleeve Gastrectomy (cVSG)

conventional vertical sleeve gastrectomy (cVSG)

Interventions

Modified Vertical Sleeve Gastrectomy (mVSG)

The modified procedure preserves the gastric sling fibers and re-establishes the gastroesophageal flap valve (GEFV).

Conventional Vertical Sleeve Gastrectomy (cVSG)

Vertical Sleeve Gastrectomy as standard procedure

Primary outcome measure

  • % Acid Exposure Time (%AET) [ Time Frame: Pre-surgery, Month 6-9 post surgery ]

Central Contacts and Locations

Central contacts

Locations

University of California, Irvine

Recruiting

Orange, California, United States, 92628

Contacts

University of California, San Diego

Recruiting

San Diego, California, United States, 92093

Contacts

Ravinder K. Mittal, MD

858-534-3328rmittal@ucsd.edu

More Information

Sponsor

University of California, Irvine

Last update posted

Jul 14, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, Irvine on 2026-07-14.